Correction: Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours

César Serrano; Adrián Mariño-Enríquez; Derrick L Tao; Julia Ketzer; Grant Eilers; Meijun Zhu; Channing Yu; Aristotle M Mannan; Brian P Rubin; George D Demetri; Chandrajit P Raut; Ajia Presnell; Arin McKinley; Michael C Heinrich; Jeffrey T Czaplinski; Ewa Sicinska; Sebastian Bauer; Suzanne George; Jonathan A Fletcher

doi:10.1038/s41416-019-0487-5

Correction: Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours

Br J Cancer. 2019 Jul;121(3):281. doi: 10.1038/s41416-019-0487-5.

Authors

César Serrano^{1

2

3}, Adrián Mariño-Enríquez⁴, Derrick L Tao⁴, Julia Ketzer⁵, Grant Eilers⁴, Meijun Zhu⁴, Channing Yu^{6

7

8}, Aristotle M Mannan⁷, Brian P Rubin⁹, George D Demetri^{6

10}, Chandrajit P Raut^{6

11}, Ajia Presnell¹², Arin McKinley¹², Michael C Heinrich¹², Jeffrey T Czaplinski⁶, Ewa Sicinska¹³, Sebastian Bauer⁵, Suzanne George⁶, Jonathan A Fletcher^{14

15}

Affiliations

¹ Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, 20 Shattuck Street, Thorn 528, Boston, MA, USA. [email protected].
² Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. [email protected].
³ Sarcoma Translational Research Laboratory, Vall d'Hebron Institute of Oncology; Department of Oncology, Vall d'Hebron University Hospital, Barcelona, Spain. [email protected].
⁴ Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, 20 Shattuck Street, Thorn 528, Boston, MA, USA.
⁵ Department of Medical Oncology, West German Cancer Center, University Hospital Essen, University Duisburg-Essen, Essen, Germany.
⁶ Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
⁷ Broad Institute of MIT and Harvard, 7 Cambridge Center, Cambridge, MA, USA.
⁸ Daiichi Sankyo Inc., Basking Ridge, NJ, USA.
⁹ Department of Molecular Genetics, Lerner Research Institute and Cleveland Clinic, 9500, Euclid Ave, Cleveland, OH, USA.
¹⁰ Ludwig Center for Cancer Research at Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
¹¹ Division of Surgical Oncology, Brigham and Women's Hospital, Harvard Medical School, Boston, 75 Francis Street, Boston, MA, USA.
¹² Portland VA Medical Center and OHSU Knight Cancer Institute, Portland, Oregon, USA.
¹³ Department of Oncologic Pathology, Dana Farber Cancer Institute, Boston, MA, USA.
¹⁴ Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, 20 Shattuck Street, Thorn 528, Boston, MA, USA. [email protected].
¹⁵ Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. [email protected].

Abstract

The additional information of this manuscript originally stated that the authors declare no competing interests. This statement was incorrect, and should instead have stated the following:M.C.H. has the following competing interests to declare: Equity interest at Molecular MD; Consulting at Molecular MD, Blueprint Medicines, Deciphera Pharmaceuticals; Expert Testimony at Novartis; Licensed patent with royalty payments at Novartis. The remaining authors have no competing interests to declare.The authors apologise for any convenience this may have caused.

Publication types

Published Erratum